Follow
Bonaventura Clotet
Bonaventura Clotet
Director irsiCaixa AIDS Research Institute
Verified email at irsicaixa.es
Title
Cited by
Cited by
Year
Combination antiretroviral therapy and the risk of myocardial infarction
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
New England Journal of Medicine 349 (21), 1993-2003, 2003
20732003
Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study
Data Collection on Adverse Events of Anti-HIV Drugs Study Group
Archives of internal medicine 166 (15), 1632-1641, 2006
14462006
Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy
AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, J Van Lunzen, ...
Jama 316 (2), 171-181, 2016
14172016
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration
D: A: D Study Group
The Lancet 371 (9622), 1417-1426, 2008
10862008
Maraviroc for previously treated patients with R5 HIV-1 infection
RM Gulick, J Lalezari, J Goodrich, N Clumeck, E DeJesus, A Horban, ...
New England Journal of Medicine 359 (14), 1429-1441, 2008
8802008
Raltegravir with optimized background therapy for resistant HIV-1 infection
RT Steigbigel, DA Cooper, PN Kumar, JE Eron, M Schechter, M Markowitz, ...
New England Journal of Medicine 359 (4), 339-354, 2008
8762008
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
A Lazzarin, B Clotet, D Cooper, J Reynes, K Arastéh, M Nelson, ...
New England Journal of Medicine 348 (22), 2186-2195, 2003
8192003
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society–USA Panel
MS Hirsch, F Brun-Vézinet, TD Richard, SM Hammer, VA Johnson, ...
Jama 283 (18), 2417-2426, 2000
8172000
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management
MS Hirsch, B Conway, TD Richard, VA Johnson, F Brun-Vézinet, B Clotet, ...
Jama 279 (24), 1984-1991, 1998
7191998
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel
MS Hirsch, F Brun-Vézinet, B Clotet, B Conway, DR Kuritzkes, ...
Clinical Infectious Diseases 37 (1), 113-128, 2003
6632003
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel
MS Hirsch, HF Günthard, JM Schapiro, FB Vézinet, B Clotet, SM Hammer, ...
Clinical Infectious Diseases 47 (2), 266-285, 2008
6532008
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
M J Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ...
Nature medicine 16 (4), 460-465, 2010
6272010
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two …
B Clotet, N Bellos, JM Molina, D Cooper, JC Goffard, A Lazzarin, ...
The Lancet 369 (9568), 1169-1178, 2007
6042007
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
A Lazzarin, T Campbell, B Clotet, M Johnson, C Katlama, A Moll, ...
The Lancet 370 (9581), 39-48, 2007
5982007
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
DA Cooper, RT Steigbigel, JM Gatell, JK Rockstroh, C Katlama, P Yeni, ...
New England Journal of Medicine 359 (4), 355-365, 2008
5872008
Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study
Strategies for Management of Antiretroviral Therapy (SMART) Study Group
The Journal of infectious diseases 197 (8), 1133-1144, 2008
5572008
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b …
B Clotet, J Feinberg, J Van Lunzen, MA Khuong-Josses, A Antinori, ...
The Lancet 383 (9936), 2222-2231, 2014
5562014
Update of the Drug Resistance Mutations in HIV-1: 2005
VA Johnson, F Brun-Vézinet, B Clotet, B Conway, D Pillay, J Schapiro, ...
Top. HIV Med 14 (3), 125-130, 2006
5042006
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3 …
CJ Cohen, J Andrade-Villanueva, B Clotet, J Fourie, MA Johnson, ...
The Lancet 378 (9787), 229-237, 2011
4402011
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …
L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ...
The Lancet infectious diseases 11 (5), 363-371, 2011
4372011
The system can't perform the operation now. Try again later.
Articles 1–20